Press release - November 20th, 2012
Cerbomed GmbH presents transcutaneous Vagus Nerve Stimulation at the 8th annual meeting of the German Society of Neuromodulation
ERLANGEN/BERLIN, Germany, November 20th, 2012 – Between November 23rd and 24th, 2012 the medical device company cerbomed GmbH, Erlangen, Germany will present the transcutaneous Vagus Nerve Stimulation (t-VNS) at the 8th annual meeting of the German Society of Neuromodulation. Participants will get first-hand information about the new therapy option for patients suffering from difficult-to-treat epilepsies, depression and pain at the booth and in the course of a symposium on November 23rd.
Transcutaneous Vagus Nerve Stimulation is addressed to patients suffering from various difficult-to-treat neurological and psychiatric diseases.
The t-VNS therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.
Cerbomed GmbH is an innovative medical device company located in Erlangen, Germany, that focuses on neuromodulation. The company, founded in 2005, focuses on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.
In 2010 cerbomed received the European clearance (CE mark) for the transcutaneous Vagus Nerve Stimulation for the treatment of epilepsies and depression, in 2012 for the treatment of pain. Currently two clinical studies are carried out regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.
In September 2012 cerbomed entered into a strategic partnership with Cyberonics, Inc., the global market leader in vagus nerve stimulation.
The therapy device NEMOS for the treatment of drug-resistant epilepsy is available in Germany and Austria.